

# Antonio Passaro

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/6020566/antonio-passaro-publications-by-citations.pdf>

**Version:** 2024-04-17

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

86  
papers

1,763  
citations

21  
h-index

40  
g-index

129  
ext. papers

2,597  
ext. citations

5.6  
avg, IF

5.16  
L-index

#	Paper	IF	Citations
86	COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study. <i>Lancet Oncology, The</i> , <b>2020</b> , 21, 914-922	21.7	328
85	Bone and brain metastasis in lung cancer: recent advances in therapeutic strategies. <i>Therapeutic Advances in Medical Oncology</i> , <b>2014</b> , 6, 101-14	5.4	135
84	Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus. <i>Annals of Oncology</i> , <b>2020</b> , 31, 1320-1335	10.3	121
83	Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC. <i>Journal of the National Cancer Institute</i> , <b>2017</b> , 109,	9.7	89
82	Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer <b>2019</b> , 7, 316		56
81	ESMO Management and treatment adapted recommendations in the COVID-19 era: Lung cancer. <i>ESMO Open</i> , <b>2020</b> , 5,	6	54
80	Immunotherapy in Non-Small-Cell Lung Cancer Patients With Performance Status 2: Clinical Decision Making With Scant Evidence. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 1863-1867	2.2	51
79	Recent Advances on the Role of EGFR Tyrosine Kinase Inhibitors in the Management of NSCLC With Uncommon, Non Exon 20 Insertions, EGFR Mutations. <i>Journal of Thoracic Oncology</i> , <b>2021</b> , 16, 764-773	8.9	47
78	Targeting EGFR T790M mutation in NSCLC: From biology to evaluation and treatment. <i>Pharmacological Research</i> , <b>2017</b> , 117, 406-415	10.2	41
77	Real-life results from the overall population and key subgroups within the Italian cohort of nivolumab expanded access program in non-squamous non-small cell lung cancer. <i>European Journal of Cancer</i> , <b>2019</b> , 123, 72-80	7.5	34
76	Understanding the Mechanisms of Resistance in -Positive NSCLC: From Tissue to Liquid Biopsy to Guide Treatment Strategy. <i>International Journal of Molecular Sciences</i> , <b>2019</b> , 20,	6.3	33
75	Combination immunotherapy strategies in advanced non-small cell lung cancer (NSCLC): Does biological rationale meet clinical needs?. <i>Critical Reviews in Oncology/Hematology</i> , <b>2017</b> , 119, 30-39	7	29
74	Treatment of advanced non-small-cell lung cancer: The 2019 AIOM (Italian Association of Medical Oncology) clinical practice guidelines. <i>Critical Reviews in Oncology/Hematology</i> , <b>2020</b> , 146, 102858	7	28
73	Activity of EGFR TKIs in Caucasian Patients With NSCLC Harboring Potentially Sensitive Uncommon EGFR Mutations. <i>Clinical Lung Cancer</i> , <b>2019</b> , 20, e186-e194	4.9	27
72	Overcoming therapy resistance in EGFR-mutant lung cancer.. <i>Nature Cancer</i> , <b>2021</b> , 2, 377-391	15.4	23
71	management of nonhematologic toxicities associated with different EGFR-TKIs in advanced NSCLC: a comparison analysis. <i>Clinical Lung Cancer</i> , <b>2014</b> , 15, 307-12	4.9	22
70	Clinical features affecting survival in metastatic NSCLC treated with immunotherapy: A critical review of published data. <i>Cancer Treatment Reviews</i> , <b>2020</b> , 89, 102085	14.4	22

69	Concise Review: Resistance to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: The Role of Cancer Stem Cells. <i>Stem Cells</i> , <b>2018</b> , 36, 633-640	5.8	21
68	Severity of COVID-19 in patients with lung cancer: evidence and challenges <b>2021</b> , 9,		21
67	Tumor Mutational Burden as a Pan-cancer Biomarker for Immunotherapy: The Limits and Potential for Convergence. <i>Cancer Cell</i> , <b>2020</b> , 38, 624-625	24.3	20
66	Personalized treatment in advanced ALK-positive non-small cell lung cancer: from bench to clinical practice. <i>OncoTargets and Therapy</i> , <b>2016</b> , 9, 6361-6376	4.4	20
65	Understanding EGFR heterogeneity in lung cancer. <i>ESMO Open</i> , <b>2020</b> , 5, e000919	6	17
64	Immunotherapy in non-small cell lung cancer harbouring driver mutations. <i>Cancer Treatment Reviews</i> , <b>2021</b> , 96, 102179	14.4	17
63	Gr-MDSC-linked asset as a potential immune biomarker in pretreated NSCLC receiving nivolumab as second-line therapy. <i>Clinical and Translational Oncology</i> , <b>2020</b> , 22, 603-611	3.6	15
62	EGFR-TKIs in non-small-cell lung cancer: focus on clinical pharmacology and mechanisms of resistance. <i>Pharmacogenomics</i> , <b>2018</b> , 19, 727-740	2.6	15
61	Results of Multilevel Containment Measures to Better Protect Lung Cancer Patients From COVID-19: The IEO Model. <i>Frontiers in Oncology</i> , <b>2020</b> , 10, 665	5.3	14
60	Diagnosis and treatment of early and locally advanced non-small-cell lung cancer: The 2019 AIOM (Italian Association of Medical Oncology) clinical practice guidelines. <i>Critical Reviews in Oncology/Hematology</i> , <b>2020</b> , 148, 102862	7	14
59	Second-line treatment of non-small-cell lung cancer: chemotherapy or tyrosine kinase inhibitors?. <i>Expert Review of Anticancer Therapy</i> , <b>2011</b> , 11, 1587-97	3.5	12
58	erbB in NSCLC as a molecular target: current evidences and future directions. <i>ESMO Open</i> , <b>2020</b> , 5,	6	12
57	Strategies to overcome resistance to immune checkpoint blockade in lung cancer. <i>Lung Cancer</i> , <b>2021</b> , 154, 151-160	5.9	12
56	Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring. <i>ESMO Open</i> , <b>2021</b> , 6, 100117	6	11
55	Molecular and clinical analysis of predictive biomarkers in non-small-cell lung cancer. <i>Current Medicinal Chemistry</i> , <b>2012</b> , 19, 3689-700	4.3	10
54	Afatinib as first-line treatment for patients with advanced non-small-cell lung cancer harboring EGFR mutations: focus on LUX-Lung 3 and LUX-Lung 6 phase III trials. <i>Journal of Thoracic Disease</i> , <b>2013</b> , 5, 383-4	2.6	10
53	Isolation and Characterization of Circulating Tumor Cells in Squamous Cell Carcinoma of the Lung Using a Non-EpCAM-Based Capture Method. <i>PLoS ONE</i> , <b>2015</b> , 10, e0142891	3.7	9
52	Managing Resistance to Immune Checkpoint Inhibitors in Lung Cancer: Treatment and Novel Strategies.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , JCO2101845	2.2	9

51	Erlotinib-associated rash in patients with EGFR mutation-positive non-small-cell lung cancer treated in the EURTAC trial. <i>Future Oncology</i> , <b>2015</b> , 11, 421-9	3.6	7
50	The Role of Performance Status in Small-Cell Lung Cancer in the Era of Immune Checkpoint Inhibitors. <i>Clinical Lung Cancer</i> , <b>2020</b> , 21, e539-e543	4.9	7
49	Biopsy and re-biopsy in lung cancer: the oncologist requests and the role of endobronchial ultrasounds transbronchial needle aspiration. <i>Journal of Thoracic Disease</i> , <b>2017</b> , 9, S405-S409	2.6	7
48	The long tail of molecular alterations in non-small cell lung cancer: a single-institution experience of next-generation sequencing in clinical molecular diagnostics. <i>Journal of Clinical Pathology</i> , <b>2018</b> , 71, 767-773	3.9	7
47	Multimodality treatment of gynecomastia in patients receiving antiandrogen therapy for prostate cancer in the era of abiraterone acetate and new antiandrogen molecules. <i>Oncology</i> , <b>2013</b> , 84, 92-9	3.6	7
46	Erlotinib and gefitinib for elderly patients with advanced non-small-cell lung cancer. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , <b>2014</b> , 14, 646-50	2.2	7
45	Efficacy of Anti-PD1/PD-L1 Therapy (IO) in KRAS Mutant Non-small Cell Lung Cancer Patients: A Retrospective Analysis. <i>Anticancer Research</i> , <b>2020</b> , 40, 427-433	2.3	7
44	Molecular features and clinical outcome of lung malignancies in very young people. <i>Future Oncology</i> , <b>2015</b> , 11, 1211-21	3.6	6
43	Afatinib in NSCLC harbouring EGFR mutations. <i>Lancet Oncology, The</i> , <b>2014</b> , 15, e148-9	21.7	6
42	Prognostic value of lymph node ratio in patients with pathological N1 non-small cell lung cancer: a systematic review with meta-analysis. <i>Translational Lung Cancer Research</i> , <b>2016</b> , 5, 258-64	4.4	6
41	Gene Fusion in Advanced Lung Cancer in Women: A Systematic Analysis, Review of the Literature, and Diagnostic Algorithm.. <i>JCO Precision Oncology</i> , <b>2017</b> , 1, 1-9	3.6	5
40	Sensitive and affordable diagnostic assay for the quantitative detection of anaplastic lymphoma kinase (ALK) alterations in patients with non-small cell lung cancer. <i>Oncotarget</i> , <b>2016</b> , 7, 37160-37176	3.3	5
39	Afatinib in first-line setting for NSCLC harbouring common EGFR mutations: new light after the preliminary results of LUX-Lung 7?. <i>Journal of Thoracic Disease</i> , <b>2016</b> , 8, E217-20	2.6	5
38	Is multidisciplinary management possible in the treatment of lung cancer? A report from three Italian meetings. <i>Radiologia Medica</i> , <b>2020</b> , 125, 214-219	6.5	5
37	Acquired Resistance to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancers: The Role of Next-Generation Sequencing on Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration Samples. <i>Archives of Pathology and Laboratory Medicine</i> , <b>2018</b> , 142, 465-473	5	4
36	Dramatic Antitumor Activity of Nivolumab in Advanced HER2-Positive Lung Cancer. <i>Clinical Lung Cancer</i> , <b>2016</b> , 17, e179-e183	4.9	4
35	SRC and PIM1 as potential co-targets to overcome resistance in MET deregulated non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , <b>2020</b> , 9, 1810-1821	4.4	4
34	The Promising Evolution of Targeted Therapeutic Strategies in Cancer. <i>Cancer Discovery</i> , <b>2021</b> , 11, 810-814	4.4	4

33	Genomic Characterization of Concurrent Alterations in Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable Mutations. <i>Cancers</i> , <b>2021</b> , 13,	6.6	4
32	The immune profile of EGFR-mutated non-small-cell lung cancer at disease onset and progression after tyrosine kinase inhibitors therapy. <i>Immunotherapy</i> , <b>2018</b> , 10, 1041-1045	3.8	4
31	Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN): a retrospective analysis of patients treated through an access program. <i>Therapeutic Advances in Medical Oncology</i> , <b>2021</b> , 13, 17588359211019675	5.4	4
30	Ceritinib compassionate use for patients with crizotinib-refractory, anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer. <i>Future Oncology</i> , <b>2018</b> , 14, 353-361	3.6	3
29	Afatinib-related nonhematologic adverse events: is common evaluation enough for now?. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 864-5	2.2	3
28	Lung Tissue Injury as an Atypical Response to Nivolumab in Non-Small Cell Lung Cancer. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2017</b> , 196, 1349-1350	10.2	3
27	Uncommon Compound Mutations in Non-Small Cell Lung Cancer (NSCLC): A Systematic Review of Available Evidence.. <i>Current Oncology</i> , <b>2022</b> , 29, 255-266	2.8	3
26	Brigatinib for the treatment of ALK-positive advanced non-small cell lung cancer patients. <i>Drugs of Today</i> , <b>2017</b> , 53, 435-446	2.5	3
25	Early Progression in Non-Small Cell Lung Cancer (NSCLC) with High PD-L1 Treated with Pembrolizumab in First-Line Setting: A Prognostic Scoring System Based on Clinical Features. <i>Cancers</i> , <b>2021</b> , 13,	6.6	3
24	Afatinib in EGFR TKI-naïve patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer: Interim analysis of a Phase 3b study. <i>Lung Cancer</i> , <b>2021</b> , 152, 127-134	5.9	3
23	Delivery of gefitinib with an immunostimulatory nanocarrier improves therapeutic efficacy in lung cancer. <i>Translational Lung Cancer Research</i> , <b>2021</b> , 10, 926-935	4.4	3
22	CheckMate 9LA: broadening treatment options for patients with non-small-cell lung cancer. <i>Lancet Oncology</i> , <b>2021</b> , 22, 157-159	21.7	3
21	Gender influence on professional satisfaction and gender issue perception among young oncologists. A survey of the Young Oncologists Working Group of the Italian Association of Medical Oncology (AIOM). <i>ESMO Open</i> , <b>2018</b> , 3, e000389	6	3
20	Benefits and Harms of Lung Cancer Screening by Chest Computed Tomography: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 2574-2585	2.2	3
19	Treatment-driven tumour heterogeneity and drug resistance: Lessons from solid tumours.. <i>Cancer Treatment Reviews</i> , <b>2022</b> , 104, 102340	14.4	2
18	ESMO expert consensus statements on the management of EGFR mutant Non-Small Cell Lung Cancer.. <i>Annals of Oncology</i> , <b>2022</b> ,	10.3	2
17	Afatinib for the first-line treatment of patients with metastatic EGFR-positive NSCLC: a look at the data. <i>Expert Review of Clinical Pharmacology</i> , <b>2016</b> , 9, 1283-1288	3.8	1
16	Vitamin supplementation in patients receiving pemetrexed for advanced non-small cell lung cancer. <i>Lung Cancer</i> , <b>2013</b> , 82, 511	5.9	1

15	Concomitant ALK translocation and other non-EGFR gene in NSCLC: knowledge in the making. <i>Annals of Oncology</i> , <b>2015</b> , 26, 1270-1271	10.3	1
14	The impact of chemotherapy on the lymphatic system in thoracic oncology. <i>Thoracic Surgery Clinics</i> , <b>2012</b> , 22, 243-9	3.1	1
13	Molecular profile in non-small cell lung cancers (NSCLCs) occurring in elderly.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 10053-10053	2.2	1
12	Neoadjuvant EGFR TKIs: toward personalized management in non-small-cell lung cancer. <i>Translational Lung Cancer Research</i> , <b>2012</b> , 1, 280-2	4.4	1
11	Afatinib in EGFR TKI-Naïve Patients with Locally Advanced or Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Pooled Analysis of Three Phase IIIb Studies. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 709877	5.3	1
10	The role of molecular heterogeneity targeting resistance mechanisms to lung cancer therapies. <i>Expert Review of Molecular Diagnostics</i> , <b>2021</b> , 21, 757-766	3.8	1
9	Afatinib for the Treatment of Non-Small Cell Lung Cancer Harboring Uncommon Mutations: An Updated Database of 1023 Cases Brief Report.. <i>Frontiers in Oncology</i> , <b>2022</b> , 12, 834704	5.3	1
8	Epidermal growth factor receptor exon 20 insertion variants in non-small cell lung cancer patients. <i>Critical Reviews in Oncology/Hematology</i> , <b>2021</b> , 169, 103536	7	0
7	First-line treatment selection with organoids of an m + m stage IA1 patient with early metastatic recurrence after radical surgery and follow-up. <i>Journal of Thoracic Disease</i> , <b>2020</b> , 12, 3764-3773	2.6	0
6	Proposals for revisions of the classification of lung cancers with multiple pulmonary sites: the radiologist's, thoracic surgeon's and oncologist's point of view. <i>Journal of Thoracic Disease</i> , <b>2016</b> , 8, E805-8	2.6	0
5	Reply. <i>Clinical Lung Cancer</i> , <b>2020</b> , 21, e415-e416	4.9	
4	Delivery optimization of erlotinib according to toxicity: may clinical practice go beyond research?. <i>Lung Cancer</i> , <b>2013</b> , 80, 352-3	5.9	
3	Non-Small Cell Lung Cancer: Common Types. <i>Cancer Dissemination Pathways</i> , <b>2020</b> , 47-61	0	
2	Rash and diarrhea with afatinib treatment in metastatic adenocarcinoma lung cancer patients (pts) unselected for epidermal growth factor receptor (EGFR) mutations: Retrospective study.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, e19165-e19165	2.2	
1	Expectations as outcome of effectiveness for patients with metastatic lung cancer. <i>Annals of Palliative Medicine</i> , <b>2013</b> , 2, 164-6	1.7	